M. G. Celeste, F. De Marco, C. Fresco, G. Musumeci, and R. Ravasio, “Budget impact analysis of dabigatran compared with rivaroxaban in the prevention of the thromboembolic risk in patients with non-valvular atrial fibrillation”, FE, vol. 18, no. 1, Nov. 2017.